Suppr超能文献

实体器官移植后复发性球孢子菌病的预防

The prevention of recrudescent coccidioidomycosis after solid organ transplantation.

作者信息

Blair Janis E, Kusne Shimon, Carey Elizabeth J, Heilman Raymond L

机构信息

Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ 85259, USA.

出版信息

Transplantation. 2007 May 15;83(9):1182-7. doi: 10.1097/01.tp.0000260143.54103.0d.

Abstract

BACKGROUND

Coccidioidomycosis is an endemic fungal infection of the southwestern United States that causes considerable morbidity and mortality in transplant recipients, often as the result of reactivated infection.

METHODS

A retrospective review of the medical records of 47 patients with prior coccidioidomycosis who underwent solid organ transplantation (18 liver, 24 kidney, 3 pancreas, and 2 combined organ) at our tertiary care academic medical center.

RESULTS

Of 47 transplant recipients with a history of coccidioidomycosis, 44 had quiescent infection at transplantation. Of the three with active coccidioidomycosis at transplantation, two were taking azole prophylaxis and had no further coccidioidal infection after transplantation. One of the three had positive serologic findings identified only on the day of transplantation, and prophylaxis was initiated a few hours after surgery along with immunosuppression; nevertheless, the treatment course was complicated by disseminated coccidioidomycosis. Seven patients did not initiate or self-discontinued prophylaxis; one patient who discontinued prophylaxis experienced recurrent pulmonary infection.

CONCLUSIONS

For patients undergoing transplantation in an area endemic for coccidioidomycosis, we recommend routine evaluation for evidence of prior infection and initiation of azole prophylaxis. For our patients with quiescent infection, azoles suppressed any recrudescent coccidioidomycosis after transplantation. The selection of patients who would benefit from prophylaxis and the optimal dose and duration of such prophylaxis should be studied further.

摘要

背景

球孢子菌病是美国西南部的一种地方性真菌感染,在移植受者中可导致相当高的发病率和死亡率,通常是再激活感染的结果。

方法

对在我们的三级医疗学术医学中心接受实体器官移植(18例肝脏、24例肾脏、3例胰腺和2例联合器官移植)的47例既往有球孢子菌病的患者的病历进行回顾性研究。

结果

47例有球孢子菌病病史的移植受者中,44例在移植时感染处于静止期。移植时3例有活动性球孢子菌病的患者中,2例正在接受唑类预防治疗,移植后未发生进一步的球孢子菌感染。3例中的1例仅在移植当天血清学检查结果呈阳性,术后数小时开始预防治疗并同时给予免疫抑制治疗;尽管如此,治疗过程仍因播散性球孢子菌病而复杂化。7例患者未开始或自行停止预防治疗;1例停止预防治疗的患者发生了复发性肺部感染。

结论

对于在球孢子菌病流行地区接受移植的患者,我们建议常规评估既往感染的证据并开始唑类预防治疗。对于我们的静止期感染患者,唑类药物可抑制移植后任何复发的球孢子菌病。应进一步研究哪些患者将从预防治疗中获益以及这种预防治疗的最佳剂量和持续时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验